Drug Trial Radar · NCT06588738
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
862
Actual
Start
Aug 20, 2024
Primary completion
Sep 23, 2025
Study completion Dec 18, 2025
Sponsor
- Lead sponsor
- Alumis IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.
Conditions
- Plaque Psoriasis
Interventions
EnvudeucitinibDrug
ESK-001
PlaceboDrug
Placebo
ApremilastDrug
Apremilast
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placeboTime frame: 16 weeks
Locations
124 sites in 12 countries. Site status is shown where the registry gives one.
Total Skin and Beauty Dermatology Center, PC
Birmingham, Alabama
Chandler Clinical Trials
Chandler, Arizona
Noble Clinical Research
Tucson, Arizona
Zenith Research Inc.
Beverly Hills, California
Raoof MD
Encino, California
Long Beach Research Institute
Long Beach, California
Dermatology Research Associates
Los Angeles, California
Empire Clinical Research - Pomona
Pomona, California
Integrative Skin Science and Research
Sacramento, California
UC San Diego
San Diego, California
Southern California Clinical Research
Santa Ana, California
Clinical Science Institute Dermatology Institute
Santa Monica, California
FXM Clinical Research Ft. Lauderdale LLC
Fort Lauderdale, Florida
Direct Helpers Research Center (DHRC)
Hialeah, Florida
AppleMed Research Group under WCG
Miami, Florida
FAX Pharma Clinical Research Inc
Miami, Florida
FXM Clinical Research - Miami LLC
Miami, Florida
Las Mercedes Medical Research
Miami, Florida
FXM Clinical Research Miramar LLC
Miramar, Florida
Renstar Medical Research
Ocala, Florida
DS Research of Southern Indiana
Clarksville, Indiana
The Indiana Clinical Trials Center
Plainfield, Indiana
DS Research of Kentucky
Louisville, Kentucky
Michigan Center for Research Company
Clarkston, Michigan
Henry Ford Medical Center - Farmington Road
Detroit, Michigan
Revival Research Institute
Troy, Michigan
Grekin Skin Institute
Warren, Michigan
Associated Skin Care Specialists - Minnesota Clinical Study Center
New Brighton, Minnesota
Schlessinger MD
Omaha, Nebraska
Las Vegas Clinical Trials
Las Vegas, Nevada
NYC Health and Hospitals Elmhurst
Elmhurst, New York
Pioneer Clinical Research NY
New York, New York
Cameron Dermatology
New York, New York
DermResearchCenter of New York
Stony Brook, New York
Asheville Clinical Trials
Asheville, North Carolina
WDC Cosmetic and Research
Wilmington, North Carolina
Optima Research Boardman
Boardman, Ohio
Clinical Partners LLC
Johnston, Rhode Island
Modern Research Associates PLLC
Dallas, Texas
SMS Clinical Research
Mesquite, Texas
Showing 40 of 124 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.